BRPI0921299A2 - Compostos de benzamida adamantila - Google Patents
Compostos de benzamida adamantilaInfo
- Publication number
- BRPI0921299A2 BRPI0921299A2 BRPI0921299-0A BRPI0921299A BRPI0921299A2 BR PI0921299 A2 BRPI0921299 A2 BR PI0921299A2 BR PI0921299 A BRPI0921299 A BR PI0921299A BR PI0921299 A2 BRPI0921299 A2 BR PI0921299A2
- Authority
- BR
- Brazil
- Prior art keywords
- benzamide compounds
- adamantyl
- adamantyl benzamide
- compounds
- benzamide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
- C07D213/643—2-Phenoxypyridines; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11681008P | 2008-11-21 | 2008-11-21 | |
PCT/US2009/064776 WO2010059618A1 (en) | 2008-11-21 | 2009-11-17 | Adamantyl benzamide compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0921299A2 true BRPI0921299A2 (pt) | 2015-08-25 |
Family
ID=42198471
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0921299-0A BRPI0921299A2 (pt) | 2008-11-21 | 2009-11-17 | Compostos de benzamida adamantila |
Country Status (13)
Country | Link |
---|---|
US (1) | US8927549B2 (pt) |
EP (1) | EP2362730A4 (pt) |
JP (1) | JP2012509879A (pt) |
KR (1) | KR20110088575A (pt) |
CN (1) | CN102223797A (pt) |
AU (1) | AU2009316802B2 (pt) |
BR (1) | BRPI0921299A2 (pt) |
CA (1) | CA2744383C (pt) |
EA (1) | EA020496B1 (pt) |
IL (1) | IL212711A0 (pt) |
MX (1) | MX2011005037A (pt) |
WO (1) | WO2010059618A1 (pt) |
ZA (1) | ZA201104551B (pt) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008515956A (ja) * | 2004-10-12 | 2008-05-15 | ノボ ノルディスク アクティーゼルスカブ | 11β−ヒドロキシステロイドデヒドロゲナーゼ1型活性スピロ化合物 |
JP2009539937A (ja) * | 2006-06-16 | 2009-11-19 | ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー | 置換型ピペリジンカルボキサミドの医薬的使用 |
EP1878721A1 (en) * | 2006-07-13 | 2008-01-16 | Novo Nordisk A/S | 4-Piperidylbenzamides as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors |
JP2010519239A (ja) * | 2007-02-23 | 2010-06-03 | ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー | 11−ベータ−ヒドロキシステロイドデヒドロゲナーゼの阻害因子としてのn−アドマンチルベンザミド |
WO2008101914A2 (en) | 2007-02-23 | 2008-08-28 | High Point Pharmaceuticals, Llc | N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase |
JP2010519240A (ja) * | 2007-02-23 | 2010-06-03 | ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー | 11−ベータ−ヒドロキシステロイドデヒドロゲナーゼの阻害剤としての、n−アダマンチルベンズアミド |
WO2008101907A2 (en) * | 2007-02-23 | 2008-08-28 | High Point Pharmaceuticals, Llc | N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase |
AU2007349112A1 (en) * | 2007-03-09 | 2008-09-18 | High Point Pharmaceuticals, Llc | Indole- and benzimidazole amides as hydroxysteroid dehydrogenase inhibitors |
JP2010522766A (ja) * | 2007-03-28 | 2010-07-08 | ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー | 11ベータ−hsd1活性化合物 |
EP2152081B1 (en) * | 2007-04-11 | 2012-10-24 | High Point Pharmaceuticals, LLC | Novel compounds |
EP2150109B1 (en) * | 2007-04-24 | 2012-09-19 | High Point Pharmaceuticals, LLC | Pharmaceutical use of substituted amides |
WO2010059618A1 (en) | 2008-11-21 | 2010-05-27 | High Point Pharmaceuticals, Llc | Adamantyl benzamide compounds |
ES2350077B1 (es) | 2009-06-04 | 2011-11-04 | Laboratorios Salvat, S.A. | Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1. |
US8513430B2 (en) | 2010-07-27 | 2013-08-20 | High Point Pharmaceuticals, Llc | Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators |
US8895552B2 (en) | 2010-09-03 | 2014-11-25 | Sumitomo Dainippon Pharma Co., Ltd. | Cyclic amide derivative |
JP2015129094A (ja) * | 2012-04-16 | 2015-07-16 | 大日本住友製薬株式会社 | アリールアミノピラゾール誘導体 |
KR101576235B1 (ko) * | 2012-11-30 | 2015-12-11 | 한국생명공학연구원 | 신규한 이치환 아다만틸 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 암 전이 억제용 약학적 조성물 |
GB201321601D0 (en) | 2013-12-06 | 2014-01-22 | Canbex Therapeutics Ltd | Modulator |
KR102648947B1 (ko) | 2017-04-26 | 2024-03-18 | 바실리어 파마슈티카 인터내셔널 리미티드 | 푸라자노벤즈이미다졸 및 이의 결정 형태의 제조 공정 |
Family Cites Families (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US592783A (en) * | 1897-11-02 | Adjustable back-rest for bicycle-seats | ||
US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
US4356108A (en) | 1979-12-20 | 1982-10-26 | The Mead Corporation | Encapsulation process |
US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
FI864875A0 (fi) * | 1986-11-28 | 1986-11-28 | Orion Yhtymae Oy | Nya farmakologiskt aktiva foereningar, dessa innehaollande kompositioner samt foerfarande och mellanprodukter foer anvaendning vid framstaellning av dessa. |
US5283352A (en) * | 1986-11-28 | 1994-02-01 | Orion-Yhtyma Oy | Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same |
YU213587A (en) * | 1986-11-28 | 1989-06-30 | Orion Yhtymae Oy | Process for obtaining new pharmacologic active cateholic derivatives |
US4851423A (en) * | 1986-12-10 | 1989-07-25 | Schering Corporation | Pharmaceutically active compounds |
US5750532A (en) * | 1986-12-10 | 1998-05-12 | Schering Corporation | Pharmaceutically active compounds |
US5272167A (en) * | 1986-12-10 | 1993-12-21 | Schering Corporation | Pharmaceutically active compounds |
DE3837825A1 (de) | 1988-11-08 | 1990-05-10 | Hoechst Ag | Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
GB8904174D0 (en) * | 1989-02-23 | 1989-04-05 | British Bio Technology | Compounds |
US5677330A (en) * | 1990-02-12 | 1997-10-14 | The Center For Innovative Technology | Medical uses of allosteric hemoglobin modifier compounds in patient care |
US5731454A (en) * | 1990-02-12 | 1998-03-24 | Virginia Commonwealth University | Allosteric modifiers of hemoglobin useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood |
US5648375A (en) * | 1990-02-12 | 1997-07-15 | Virginia Commonwealth University | Use of hydrophobic compounds and anesthetics in combination with allosteric hemoglobin modifiers |
US5432191A (en) * | 1990-02-12 | 1995-07-11 | The Center For Innovative Technology | Allosteric hemoglobin modifiers to decrease oxygen affinity in blood |
US5382680A (en) * | 1990-12-07 | 1995-01-17 | The Center For Innovative Technology | Allosteric hemoglobin modifier compounds |
US5705521A (en) * | 1990-02-12 | 1998-01-06 | The Center For Innovative Technology | Use of allosteric hemoglobin modifiers in combination with radiation therapy to treat carcinogenic tumors |
US5591892A (en) * | 1990-02-12 | 1997-01-07 | Center For Innovative Technology | Allosteric modifiers of hemoglobin |
US5122539A (en) * | 1990-02-12 | 1992-06-16 | Center For Innovative Technology | Allosteric hemoglobin modifiers useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood |
US5049695A (en) * | 1990-02-12 | 1991-09-17 | Center For Innovative Technology | Allosteric hemoglobin modifiers |
US5290803A (en) * | 1990-02-12 | 1994-03-01 | The Center Of Innovative Technology | Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood |
CA2053340C (en) | 1990-10-18 | 2002-04-02 | Timothy P. Burkholder | Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace |
US5872282A (en) * | 1990-12-07 | 1999-02-16 | Virginia Commonwealth University | Allosteric modifiers of hemoglobin |
US5260325A (en) * | 1991-08-19 | 1993-11-09 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking tertiary amides |
US5258407A (en) * | 1991-12-31 | 1993-11-02 | Sterling Winthrop Inc. | 3,4-disubstituted phenols-immunomodulating agents |
DE122006000015I1 (de) | 1993-06-21 | 2006-06-29 | Novo Nordisk As | Asp-B28-Insulinkristalle |
US5395846A (en) * | 1993-06-25 | 1995-03-07 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Amino Bi- and tri-carbocyclic aklane bis-aryl squalene synthase inhibitors |
FR2708608B1 (fr) * | 1993-07-30 | 1995-10-27 | Sanofi Sa | Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant. |
ES2152989T3 (es) * | 1993-08-10 | 2001-02-16 | Black James Foundation | Ligandos para los receptores de gastrina y cck. |
AU682061B2 (en) | 1993-09-17 | 1997-09-18 | Novo Nordisk A/S | Acylated insulin |
GB9409150D0 (en) * | 1994-05-09 | 1994-06-29 | Black James Foundation | Cck and gastrin receptor ligands |
WO1995032949A1 (en) * | 1994-05-27 | 1995-12-07 | James Black Foundation Limited | Gastrin and cck antagonists |
US5795907A (en) * | 1994-05-27 | 1998-08-18 | James Black Foundation Limited | Gastin and CCK receptor ligands |
US5504188A (en) | 1994-06-16 | 1996-04-02 | Eli Lilly And Company | Preparation of stable zinc insulin analog crystals |
JPH0848662A (ja) | 1994-08-05 | 1996-02-20 | Fujirebio Inc | 2−オキシベンズアミド誘導体 |
GB9517622D0 (en) | 1995-08-29 | 1995-11-01 | Univ Edinburgh | Regulation of intracellular glucocorticoid concentrations |
US6001879A (en) * | 1995-08-30 | 1999-12-14 | Bayer Aktiengesellschaft | Acylaminosalicylic acid amides and their uses as pesticides |
FR2741878B1 (fr) * | 1995-12-01 | 1998-01-09 | Cird Galderma | Composes biaromatiques portant un groupement adamantyl en ortho, compositions pharmaceutiques et cosmetiques les contenant et utilisations |
GB9525828D0 (en) | 1995-12-18 | 1996-02-21 | Bayer Ag | Use of hetarylacetic acid derivatives |
GB9526560D0 (en) | 1995-12-27 | 1996-02-28 | Bayer Ag | Use of 2-Amino-Heterocycles |
WO1997026265A1 (en) | 1996-01-17 | 1997-07-24 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use |
UA72181C2 (uk) | 1996-08-30 | 2005-02-15 | Ново Нордіск А/С | Похідна глюкагоноподібного пептиду-1 (варіанти), фармацевтична композиція та спосіб одержання лікувального засобу (варіанти), спосіб лікування діабету (варіанти) і ожиріння |
HUP0301101A3 (en) | 1996-12-31 | 2009-03-30 | Reddy S Res Foundation | Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases |
AU738197C (en) * | 1997-04-22 | 2002-05-16 | Cocensys, Inc. | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof |
WO1999001423A1 (en) | 1997-07-01 | 1999-01-14 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
CN1264384A (zh) | 1997-07-16 | 2000-08-23 | 诺沃挪第克公司 | 稠合1,2,4-噻二嗪衍生物及其制备方法和用途 |
WO1999019313A1 (en) | 1997-10-27 | 1999-04-22 | Dr. Reddy's Research Foundation | Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them |
AUPP982399A0 (en) | 1999-04-19 | 1999-05-13 | Fujisawa Pharmaceutical Co., Ltd. | Mmp inhibitor |
IL146871A0 (en) | 1999-06-02 | 2002-08-14 | Nps Pharma Inc | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases |
US6479552B2 (en) * | 1999-09-23 | 2002-11-12 | G.D. Searle & Co. | Use of substituted N, N-disubstituted diamino compounds for inhibiting cholesteryl ester transfer protein activity |
SE0001899D0 (sv) | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
AU2001276378A1 (en) | 2000-07-05 | 2002-01-14 | Bayer Aktiengesellschaft | Regulation of human 11 beta-hydroxysteroid dehydrogenase 1-like enzyme |
US7129242B2 (en) * | 2000-12-06 | 2006-10-31 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto |
GB0105772D0 (en) | 2001-03-08 | 2001-04-25 | Sterix Ltd | Use |
GB0107383D0 (en) | 2001-03-23 | 2001-05-16 | Univ Edinburgh | Lipid profile modulation |
CA2465326C (en) * | 2001-11-01 | 2011-03-29 | Icagen, Inc. | Pyrazolopyrimidines for decreasing ion flow through a voltage-dependent sodium channel |
WO2003065983A2 (en) | 2002-02-01 | 2003-08-14 | Merck & Co., Inc. | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia |
BR0307735A (pt) | 2002-02-19 | 2005-01-25 | Upjohn Co | Carboxamidas heteroaromáticas com ligação-n em ponte biciclìcas fundidas para o tratamento de doença |
AU2003226149A1 (en) * | 2002-04-05 | 2003-10-27 | Merck & Co., Inc. | Substituted aryl amides |
WO2003086410A1 (en) | 2002-04-05 | 2003-10-23 | The University Of Edinburgh | Pharmaceutical compositions comprising a 11-beta hydroxysteroid dehydrogenase inhibitor and a diuretic agent |
CA2501611A1 (en) | 2002-10-11 | 2004-04-22 | Astrazeneca Ab | 1,4-disubstituted piperidine derivatives and their use as 11-betahsd1 inhibitors |
OA12969A (en) | 2002-12-11 | 2006-10-13 | Pharmacia & Upjohn Co Llc | Combination for the treatment of ADHD. |
WO2004056744A1 (en) * | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors |
TW200503994A (en) | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
US7320989B2 (en) * | 2003-02-28 | 2008-01-22 | Encysive Pharmaceuticals, Inc. | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists |
AU2004226452B2 (en) | 2003-03-26 | 2008-07-24 | Merck Sharp & Dohme Corp. | Bicyclic piperidine derivatives as melanocortin-4 receptor agonists |
EP1615667A2 (en) | 2003-04-11 | 2006-01-18 | Novo Nordisk A/S | Combinations of an 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist |
JP2006522750A (ja) | 2003-04-11 | 2006-10-05 | ノボ ノルディスク アクティーゼルスカブ | 代謝性症候群ならびに関連の疾患および障害を治療するために、11β−ヒドロキシステロイドデヒドロゲナーゼ1型阻害剤および抗高血圧剤を使用する併用療法 |
JP2006522747A (ja) | 2003-04-11 | 2006-10-05 | ノボ ノルディスク アクティーゼルスカブ | 縮合1,2,4−トリアゾールの薬学的使用 |
US7700583B2 (en) * | 2003-04-11 | 2010-04-20 | High Point Pharmaceuticals, Llc | 11β-hydroxysteroid dehydrogenase type 1 active compounds |
EP1615697A2 (en) | 2003-04-11 | 2006-01-18 | Novo Nordisk A/S | New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof |
US20060094699A1 (en) * | 2003-04-11 | 2006-05-04 | Kampen Gita Camilla T | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy |
US7501405B2 (en) * | 2003-04-11 | 2009-03-10 | High Point Pharmaceuticals, Llc | Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders |
US20070270408A1 (en) * | 2003-04-11 | 2007-11-22 | Novo Nordisk A/S | Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines |
EP2239012A3 (en) | 2003-04-11 | 2011-06-15 | High Point Pharmaceuticals, LLC | Substituted amide derivatives and pharmaceutical uses thereof |
WO2005013950A2 (en) | 2003-08-08 | 2005-02-17 | Avanir Pharmaceuticals | Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases |
DE102004009238A1 (de) | 2004-02-26 | 2005-09-08 | Merck Patent Gmbh | Arylamid-Derivate |
US20050261302A1 (en) * | 2004-04-29 | 2005-11-24 | Hoff Ethan D | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application |
ATE397586T1 (de) * | 2004-05-07 | 2008-06-15 | Janssen Pharmaceutica Nv | Adamantyl pyrrolidin-2-on-derivate als 11-beta hydroxysteroid dehydrogenas inhibitoren |
KR100927563B1 (ko) | 2004-08-06 | 2009-11-23 | 오쓰까 세이야꾸 가부시키가이샤 | 방향족 화합물 |
CA2579002C (en) | 2004-09-02 | 2012-11-27 | Genentech, Inc. | Pyridyl inhibitors of hedgehog signalling |
JP2008515956A (ja) | 2004-10-12 | 2008-05-15 | ノボ ノルディスク アクティーゼルスカブ | 11β−ヒドロキシステロイドデヒドロゲナーゼ1型活性スピロ化合物 |
WO2006044645A2 (en) | 2004-10-13 | 2006-04-27 | Adolor Corporation | Sulfamoyl benzamides and methods of their use |
EP1655283A1 (en) | 2004-11-08 | 2006-05-10 | Evotec OAI AG | 11beta-HSD1 Inhibitors |
CA2587153A1 (en) | 2004-11-18 | 2006-05-26 | Incyte Corporation | Inhibitors of 11-.beta. hydroxyl steroid dehydrogenase type 1 and methods of using the same |
KR101302627B1 (ko) | 2005-01-05 | 2013-09-10 | 아비에 인코포레이티드 | 11-베타-하이드록시스테로이드 데하이드로게나제 타입 1 효소의 억제제 |
US7511175B2 (en) * | 2005-01-05 | 2009-03-31 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
CN101133026B (zh) | 2005-03-03 | 2011-07-06 | 霍夫曼-拉罗奇有限公司 | 作为治疗Ⅱ型糖尿病用的11β-羟基类固醇脱氢酶抑制剂的1-磺酰基-哌啶-3-羧酸酰胺衍生物 |
JP5140577B2 (ja) | 2005-03-31 | 2013-02-06 | タケダ カリフォルニア インコーポレイテッド | ヒドロキシステロイドデヒドロゲナーゼ阻害剤 |
US20060235028A1 (en) | 2005-04-14 | 2006-10-19 | Li James J | Inhibitors of 11-beta hydroxysteroid dehydrogenase type I |
CN1736485A (zh) | 2005-06-29 | 2006-02-22 | 上海美迪西生物医药有限公司 | 香草醛受体激动剂用于制备抗阿尔茨海默病产品的用途 |
WO2007051811A2 (en) | 2005-11-01 | 2007-05-10 | Transtech Pharma | Pharmaceutical use of substituted amides |
EP1948190A2 (en) * | 2005-11-01 | 2008-07-30 | Transtech Pharma | Pharmaceutical use of substituted amides |
US7544676B2 (en) | 2005-11-10 | 2009-06-09 | Adolor Corporation | Sulfamoyl benzamides and methods of their use |
ZA200804445B (en) | 2005-12-05 | 2009-11-25 | Otsuka Pharma Co Ltd | Diarylether derivatives as antitumor agents |
JP5089185B2 (ja) | 2006-02-02 | 2012-12-05 | 大塚製薬株式会社 | コラーゲン産生抑制剤。 |
BRPI0709596A2 (pt) | 2006-03-16 | 2011-07-19 | Renovis Inc | compostos bicicloeteroarila como moduladores de p2x7 e seus usos |
JP2009530346A (ja) | 2006-03-21 | 2009-08-27 | ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー | メタボリックシンドロームの治療用のアダマンタン誘導体 |
WO2007115935A1 (en) | 2006-04-07 | 2007-10-18 | High Point Pharmaceuticals, Llc | 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS |
JP2009539937A (ja) * | 2006-06-16 | 2009-11-19 | ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー | 置換型ピペリジンカルボキサミドの医薬的使用 |
US8048908B2 (en) * | 2006-07-13 | 2011-11-01 | High Point Pharmaceuticals, Llc | 11β-hydroxysteroid dehydrogenase type 1 active compounds |
EP1878721A1 (en) * | 2006-07-13 | 2008-01-16 | Novo Nordisk A/S | 4-Piperidylbenzamides as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors |
JP2010519239A (ja) | 2007-02-23 | 2010-06-03 | ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー | 11−ベータ−ヒドロキシステロイドデヒドロゲナーゼの阻害因子としてのn−アドマンチルベンザミド |
WO2008101914A2 (en) * | 2007-02-23 | 2008-08-28 | High Point Pharmaceuticals, Llc | N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase |
JP2010519240A (ja) * | 2007-02-23 | 2010-06-03 | ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー | 11−ベータ−ヒドロキシステロイドデヒドロゲナーゼの阻害剤としての、n−アダマンチルベンズアミド |
WO2008101907A2 (en) * | 2007-02-23 | 2008-08-28 | High Point Pharmaceuticals, Llc | N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase |
AU2007349112A1 (en) | 2007-03-09 | 2008-09-18 | High Point Pharmaceuticals, Llc | Indole- and benzimidazole amides as hydroxysteroid dehydrogenase inhibitors |
JP2010522766A (ja) | 2007-03-28 | 2010-07-08 | ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー | 11ベータ−hsd1活性化合物 |
EP2152081B1 (en) * | 2007-04-11 | 2012-10-24 | High Point Pharmaceuticals, LLC | Novel compounds |
EP2150109B1 (en) * | 2007-04-24 | 2012-09-19 | High Point Pharmaceuticals, LLC | Pharmaceutical use of substituted amides |
US20090281089A1 (en) | 2008-04-11 | 2009-11-12 | Genentech, Inc. | Pyridyl inhibitors of hedgehog signalling |
TW201030001A (en) | 2008-11-14 | 2010-08-16 | Amgen Inc | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors |
WO2010059618A1 (en) | 2008-11-21 | 2010-05-27 | High Point Pharmaceuticals, Llc | Adamantyl benzamide compounds |
US8513430B2 (en) * | 2010-07-27 | 2013-08-20 | High Point Pharmaceuticals, Llc | Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators |
-
2009
- 2009-11-17 WO PCT/US2009/064776 patent/WO2010059618A1/en active Application Filing
- 2009-11-17 KR KR1020117013921A patent/KR20110088575A/ko active Search and Examination
- 2009-11-17 EA EA201170703A patent/EA020496B1/ru not_active IP Right Cessation
- 2009-11-17 EP EP09828106A patent/EP2362730A4/en not_active Ceased
- 2009-11-17 MX MX2011005037A patent/MX2011005037A/es active IP Right Grant
- 2009-11-17 US US13/128,045 patent/US8927549B2/en not_active Expired - Fee Related
- 2009-11-17 CA CA2744383A patent/CA2744383C/en not_active Expired - Fee Related
- 2009-11-17 JP JP2011537550A patent/JP2012509879A/ja active Pending
- 2009-11-17 AU AU2009316802A patent/AU2009316802B2/en not_active Ceased
- 2009-11-17 BR BRPI0921299-0A patent/BRPI0921299A2/pt not_active IP Right Cessation
- 2009-11-17 CN CN2009801462081A patent/CN102223797A/zh active Pending
-
2011
- 2011-05-05 IL IL212711A patent/IL212711A0/en unknown
- 2011-06-21 ZA ZA2011/04551A patent/ZA201104551B/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2010059618A1 (en) | 2010-05-27 |
EP2362730A4 (en) | 2012-08-29 |
EP2362730A1 (en) | 2011-09-07 |
KR20110088575A (ko) | 2011-08-03 |
CN102223797A (zh) | 2011-10-19 |
IL212711A0 (en) | 2011-07-31 |
MX2011005037A (es) | 2011-06-16 |
AU2009316802B2 (en) | 2015-02-26 |
EA201170703A1 (ru) | 2012-01-30 |
AU2009316802A1 (en) | 2010-05-27 |
EA020496B1 (ru) | 2014-11-28 |
CA2744383A1 (en) | 2010-05-27 |
ZA201104551B (en) | 2012-03-28 |
US20110224244A1 (en) | 2011-09-15 |
US8927549B2 (en) | 2015-01-06 |
JP2012509879A (ja) | 2012-04-26 |
CA2744383C (en) | 2017-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0921299A2 (pt) | Compostos de benzamida adamantila | |
CY2019011I2 (el) | C7-φθορο υποκατεστημενες ενωσεις τετρακυκλινης | |
DK2288375T3 (da) | Pegylerede insulin-lispro-forbindelser | |
BRPI0920707A2 (pt) | compostos | |
DK2242759T3 (da) | Forbindelser | |
BRPI0813500A2 (pt) | Compostos antivirais | |
BRPI0821086A2 (pt) | Compostos inseticidas | |
BRPI0821868A2 (pt) | Grânulo | |
ATE502948T1 (de) | Substituierte bicyclolactamverbindungen | |
DK2340021T3 (da) | Substituerede pyrrolidin-2-carboxamider | |
BRPI0811264A2 (pt) | Compostos | |
DK2297162T3 (da) | Forbindelser | |
BRPI0814424A2 (pt) | Compostos heterociclila | |
BRPI0810702A2 (pt) | Catalisador | |
BRPI0919561A2 (pt) | tensionador | |
BRPI0916432A2 (pt) | compostos | |
BRPI0919170A2 (pt) | tensionador | |
BRPI0922098A2 (pt) | composto inorgânicos | |
BRPI0809996A2 (pt) | Compostos | |
BRPI0923592A2 (pt) | composto | |
BRPI0911393A2 (pt) | composto de 5-hidroxipirimidina-4-carboxamida | |
BRPI0815181A2 (pt) | Compostos | |
DK2206698T3 (da) | Ethynylindolforbindelser | |
BRPI0922152A2 (pt) | Compostos | |
BRPI0814613A2 (pt) | Compostos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2386 DE 27-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |